Half-Year 2022 Financial and Clinical Trials Update
Tecentriq
Anti-PD-L1 cancer immunotherapy - hepatocellular carcinoma
Indication
1L hepatocellular carcinoma (HCC)
Adjuvant hepatocellular carcinoma (HCC)
Phase/study
Phase III
IMbrave 150
# of patients
N=501
ARM A: Tecentriq plus Avastin
ARM B: Sorafenib
Design
Primary endpoint
Status
CT Identifier
Overall survival and progression free survival
FPI Q1 2018
Recruitment completed Q1 2019
Data presented at ESMO Asia 2019
■ US filing completed under RTOR Q1 2020; filed in EU Q1 2020
■ Data published in NEJM 2020;382:1894-1905
Approved in US Q2 2020 and EU Q4 2020
NCT03434379
Phase III
IMbrave050
N=668
■ ARM A: Tecentriq plus Avastin
ARM B: Active surveillance
Recurrence-free survival
FPI Q4 2019
Recruitment completed Q4 2021
PD-L1-Programmed cell death-ligand 1; ESMO-European Society for Medical Oncology; NEJM-New England Journal of Medicine; RTOR=Real time oncology review
NCT04102098
93
Roche
OncologyView entire presentation